Enhancing Alcohol Treatment Engagement in Associated Liver Disease (ALD) Patients
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorHenry Ford Health System
About this trial
The purpose of this trial is to see if providing patients with alcohol-related liver disease with tailored alcohol use treatment options will increase engagement with treatment and correct possible misconceptions.
Eligibility criteria
Qualifiers
Willingness to comply with all study procedures and availability for the duration of the study
Willing and able to provide informed consent
Enrolled at University of Michigan (UM) hepatology clinics or inpatients at UM Hospitals
Documented diagnosis of alcohol-related liver disease (ALD) (per protocol)
Disqualifiers
Unable to provide voluntary informed consent for any reason
Substantially cognitively impaired as evidenced by Westhaven grade 2 or higher hepatic encephalopathy or a score >=10 on the Short Blessed Test for cognitive impairment.
Unable to read or understand English
Undergoing active evaluation for liver transplantation, is listed for liver transplant, or is post-transplantation
Trial design
Treatments tested in this trial
- ENGAGE-ALD Application (APP)
- Treatment Facilitation bundle
- Enhanced Usual Care
Treatment groups
268 Participants
are divided into 6 treatment groups6
Treatment groupsSee each treatment group below.
Sponsors and collaborators
Henry Ford Health System
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Collaborator
Source ClinicalTrials.gov